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Abstract
Background: Malfunction of the SLC26A4 protein
leads to prelingual deafness often associated with
mild thyroid dysfunction and goiter. It is assumed that
SLC26A4 acts as a chloride/anion exchanger
responsible for the iodide organification in the thyroid
gland, and conditioning of the endolymphatic fluid in
the inner ear. Methods: Chloride uptake studies were
made using HEK293-Phoenix cells expressing human
wild type SLC26A4 (pendrin) and a mutant
(SLC26A4S28R) we recently described in a patient with
hypothyroidism, goiter and sensorineural hearing
loss. Results: Experiments are summarized showing
the functional characterization of wild type SLC26A4
and a mutant (S28R), which we described recently.
This mutant protein is transposed towards the cell
membrane, however, its transport capability is
markedly reduced if compared to wild-type SLC26A4.
Furthermore, we show that the SLC26A4 induced
chloride uptake in HEK293-Phoenix cells competes
with iodide, and, in addition, that the chloride uptake
can be blocked by NPPB and niflumic acid, whereas
DIDS is ineffective. Conclusions: The functional
characteristics of SLC26A4S28R we describe here, are
consistent with the clinical phenotype observed in the
patient from which the mutant was derived.
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Introduction
In recent years a large number of genes have been
identified that are crucially involved in the genesis of
human diseases, as, for instance, the SLC26A4 gene, that
is involved in Pendred syndrome [1]. The SLC26A4
protein is a member of a unique family of eleven anion-
transporters described so far (SLC26A1-11, A10 is
reported to be a pseudogene). SLC26 proteins do transport
anions, and some of them do exchange chloride for
another anion, which, however, can be different with
respect to the different SLC26 proteins and/or the tissue
in which the particular protein members are expressed,
i.e. HCO3-, OH-, SO42-, I-, formate- or oxalate- [2]. The
human SLC26A4 gene is located on chromosome 7 at
position 7q31 and consists of 21 exons. A domain search
reveals a sulfate transporter domain (pfam 00916.11),
which in the case of SLC26A4 is most likely involved in
chloride/anion exchange, as well as a STAS domain
(pfam 01740.11). The STAS domain is located on the C-
terminus of the protein and it was hypothesized that this
domain could be involved in nucleotide binding [3]. The
open reading frame of the SLC26A4 gene codes for a
780 amino acid protein, comprising 12 predicted trans-
membrane domains with both, the C-terminus as well as
the N-terminus, located at the cytoplasmatic side [4, 5].
The SLC26A4 protein is mainly expressed in the thyroid
gland, inner ear and the kidney and its malfunction leads
to the Pendred syndrome (PS; OMIM 274600), therefore
the SLC26A4 protein is also referred to as the Pendred
syndrome protein. Pendred syndrome is considered one
of the most common forms of syndromic deafness
accounting for up to 7.5% of cases of childhood deafness
[6].
More than 150  different mutations of the SLC26A4
gene have been found in humans so far
(www.medicine.uiowa.edu/pendredandbor). Clinically, the
patients have severe or profound sensorineural hearing
loss, associated with enlargement of the vestibular
aqueduct and of the endolymphatic duct and sac [7]. The
hearing symptoms are associated with a positive
perchlorate test, whereas goiter and hypothyroidism can
be diagnosed in about half of the cases [8]. However, the
detailed function of the SLC26A4 protein and the
respective altered functions of the mutated SLC26A4
proteins are still elusive.
The aim of the present work was to get further
insight into the function of the PDS protein in human cells.
We were particularly interested in the relation between
iodide and chloride transport by the protein. This issue is
of considerable clinical importance (with respect to the
function of the thyroid gland) in patients with Pendred
syndrome. Additionally, we were interested in testing
substances that could modify the SLC26A4 induced ion
transport, and therefore providing a pharmacological tool
to characterize cells expressing SLC26A4 protein.
Furthermore we aimed to compare the wild-type function
of SLC26A4 with a mutant form of SLC26A4, i.e.
SLC26A4S28R, which we have recently described from a
patient with Pendred syndrome. This mutation is biallelic,
and associated with goiter, positive perchlorate test,
hypothyroidism, severe sensorineural hearing loss, and
enlargement of the vestibular aqueduct as well as of the
endolymphatic duct and sac [9].
Material and Methods
Cloning of SLC26A4 cDNA
Standard procedures were used for DNA preparation,
cloning, purification, and sequencing. The human wild-type
SLC26A4 cDNA was obtained by RT-PCR, using total RNA
from normal human thyroid tissue and Taq PLATINUM Pfx
DNA polymerase (Invitrogen,-Life Technologies). The
SLC26A4 open reading frame was cloned into two different
vectors. The first vector was pTARGET, where six histidines
were added to the C-terminus of SLC26A4 for localizing the
overexpressed protein by using anti-His-tag antibodies. For
this procedure the primer-pair was: sense,
5’-GTT GGA TCC GCG AGC AGA GAC AGG TCA-3’; antisense,
5’-CTG CGC GGC CGC TCA GTG GTG GTG GTG GTG GTG
GGA TGC AAG TGT ACG CAT A -3’. The primers contained
appropriate linkers for cloning the SLC26A4 cDNA into the
BamH I and Not I sites of the pTARGET plasmid (Promega).
The second vector was pIRES2-EGFP (Clontech), where
SLC26A4 cDNA was subcloned, using the following primer:
sense, 5'-GTA ATT ACT CGA GAG ACA GGT CAT GGC AGC
G-3'; antisense, 5'-GAA TCC GGA TCC TCA AGA AGC AAG
TGT ACG CAT AGC CTC-3'. For the functional studies (chloride
uptake and the respective measurements of the transfection
efficiency), the pIRES2-EGFP vector was used, in which the
wild-type or the mutated pendrin cDNA was ligated. The use
of this vector allows the simultaneous expression of two
individual cDNA’s from a single bicistronic mRNA without the
need of physically combining the two cDNA products, i.e. to
produce tandem-proteins [10]. Therefore, since EGFP
expression occurs only if preceded by pendrin or mutated
pendrin expression, the positive transfected cells can be
individuated optically by measuring the fluorescent light emitted
by EGFP. The EGFP fluorescence (Excitation maximum = 488
nm; emission maximum = 507 nm) allows to optimize the
transfection procedure and to measure the transfection
efficiency.
Dossena/Vezzoli/Cerutti/Bazzini/Tosco/Sironi/Rodighiero/Meyer/
Fascio/Fürst/Ritter/Fugazzola/Persani/Zorowka/Storelli/Beck-Peccoz/
Bottà/Paulmichl
Cell Physiol Biochem 2006;17:245-256
D
ow
nl
oa
de
d 
by
: 
15
9.
14
9.
19
2.
11
6 
- 5
/3
/2
01
6 
2:
31
:2
6 
PM
247
Mutagenesis
The SLC26A4S28R mutant was made using the Quik
Change site-directed mutagenesis kit (Stratagene) according
to the manufacturer’s protocol, using the following primers:
sense 5'-CGG CCG GTC TAC AGA GAG CTC GCT TTC CA-3';
antisense 5'-TGG AAA GCG AGC TCT  CTG TAG ACC GGC
CG-3'. The mutants were fully sequenced before testing at the
functional level.
RT-PCR
Total RNA was isolated from HEK293-Phoenix and WRO
cells with the Qiagen RNAeasy kit as specified by the
manufacturer. RNA (2 µg) was reverse transcribed by using
Superscript II RT (Invitrogen). In one set of experiments, using
HEK293-Phoenix mRNA, the PCR reactions were performed by
using a standard Taq polymerase (Bioline), and the following
primer pair: sense: 5'-CGA TGG GAA CCA GGA ATT CA-3';
antisense: 5'-TCT CAG GAC CAC AGT CAA CA-3'. The
amplification product obtained was cloned into pSTBlue1 vector
and sequenced (MWG Biotech, Germany). In a second set of
experiments, RT-PCR analysis was performed by using both
HEK293-Phoenix and WRO mRNA with the following primers
[11]: SLC26A4: sense: 5'-AGC AGA GAC AGG TCA TGG CA-
3'; antisense: 5'-ATC CGA CAG GAA CTG CAG CT-3', beta-
actin: sense: 5’CAC AGC TTC TCC TTA ATG TCA CG-
3';antisense:5'-CGA GGC CCA GAG CCA AGA CA-3'. The
annealing temperature was 62 °C and 32 cycles were used for
amplification. These are the same conditions used by Arturi et
al. [11] for semi-quantitative PCR of the pendrin mRNA.
Western-blots and membrane preparations
Cells (native HEK293-Phoenix and WRO) from a Ø 100
mm Petri dish at -80 °C were resuspended in 1 ml of buffer A (20
mM Tris-HCl pH 7,5, 150 mM NaCl, 1 mM EDTA, 1% NP40)
supplemented with protease inhibitors (aprotinin, leupeptin,
and pepstatin, each at a concentration of 1 µg/ml) and lysed
using a syringe with a small gauge needle. Rat kidney samples
were homogenized in buffer B (0.25 M sucrose, 30 mM histidine,
and 1 mM EDTA, pH 7.2, supplemented with protease inhibitors,
1 ml/100 mg tissue) using a Teflon-glass Potter homogenizer.
Homogenates were centrifuged at 4000 x g for 15 min at 4 °C to
remove cell debris.
Table 1. Composition of
the different extracellular
solutions used for
measuring the chloride
uptake in the presence of
high extracellular iodide
concentrations.
For membrane protein extraction, from transfected cells,
we used the “Plasma Membrane Protein Extraction Kit” from
MBL International Corporation following the manufacturer
instructions. Protein was assayed by the Bradford method
(BIO-RAD, Germany). Total (10-30 µg) and plasmatic membrane
proteins (2 µg) were fractionated by SDS electrophoresis on
9% acrylamide gel and electrotransferred onto nitrocellulose
membranes (Trans-Blot Transfer medium, Biorad). After
treatment with PBS supplemented with 5% non-fat dry milk
and 0.2% Tween 20 (Sigma), membranes were incubated
overnight at 4 °C with 40 µg/ml IgG from pAb 827 kindly provided
by Prof. Bernard Rousset [12]. After three washings in PBS-
0.2% Tween solution, membranes were incubated for 1 h at
room temperature with a 1:10000 dilution of peroxidase-coupled
goat anti-rabbit antibody. Antibody-protein complexes were
then detected using the ECL PLUS detection kit (Amersham
Biosciences) followed by autoradiography.
Cell culture and transient transfection
HEK293-Phoenix cells (this is a second generation
retrovirus producing cell line for the generation of helper free
ectopic and amphotropic retroviruses) were grown in Minimum
Essential Eagle Medium (Sigma) supplemented with 10% fetal
bovine serum (Cambrex Bio Science), 2 mM L-glutamine, 100
units/ml penicillin, 100 µg/ml streptomycin and 1 mM pyruvic
acid (sodium salt). WRO cells (this is a human cell line derived
from a follicular carcinoma; [13]) were grown in Dulbecco’s
modified Eagle’s medium (Sigma), supplemented with 2 mM L-
glutamine, 1 mM pyruvic acid, 100 units/ml penicillin, 100 µg/
ml streptomycin and 10% fetal bovine serum. The cells were
maintained at 37 °C in a 5% CO2:95% air humidified incubator;
subcultures were routinely established every second to third
day by seeding cells in Petri dishes (Ø 100 mm) after trypsin/
EDTA treatment.
For uptake experiments, cells were transiently transfected
with wild-type SLC26A4 or SLC26A4S28R (both cloned into
pIRES2-EGFP plasmids); negative controls were performed on
cells transfected with empty plasmid (pIRES2-EGFP only). The
day before transfection, cells were seeded in poly-L-lysine-
treated 24-well plates and grown to 60% to 80% confluency.
HEK293-Phoenix cells were transfected by calcium phosphate
precipitation; for each well, 0.9 µg of plasmid dissolved in 13.5
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µl of water were mixed with 1.5 µl of buffer A (2.5 M CaCl2, pH
5.8) and with 15 µl of buffer B (140 mM NaCl, 1.5 mM Na2HPO4,
50 mM HEPES, pH 7.05 adjusted with NaOH). WRO cells were
transfected by using Metafectene (BionTex); for each well, 1
µg of plasmid dissolved in 30 µl of culture medium (without
serum and antibiotics) was mixed with 3 µl of Metafectene
dissolved in 30 µl of the culture medium as described above.
After an incubation of 20-30 min at room temperature (HEK293-
Phoenix and WRO), the transfection mix was spread over the
cells; after 8-10 hours, the cells were washed twice with fresh
culture medium.
For immunocytochemistry, cells were seeded on glass
coverslips (Ø 10 mm) and transfected as previously described
with the pTARGET vector coding for wild-type SLC26A4 or
SLC26A4S28R, or with the empty plasmid (negative controls).
For co-localization studies, cells were co-transfected with wild-
type SLC26A4 or SLC26A4S28R and pEYFP-mem (Clontech)
plasmids (1:1 ratio).
Chloride uptake studies
The cells were seeded and transfected as described above,
and used for uptake experiments 30 hours after transfection.
Usually, cells were washed at room temperature with 2 ml of
incubation buffer (Hanks’ balanced salt solution; Sigma)
supplemented with 10 mM HEPES and 20 mM mannitol, and
then incubated for 2 min with 300 µl of the same buffer
supplemented with 3-4 mM 36Cl- (specific activity 2 µCi/ml).
After incubation, cells were washed three times with 2 ml of
ice-cold incubation buffer and solubilized with 300 µl 0.1 M
NaOH, 0.1% (wt/vol) sodium dodecyl sulfate and 2% Na2CO3;
the lysate was centrifuged at 4000 rpm for 10 min, and the
radioactivity in the supernatant was counted by liquid
scintillation spectrometry (1600 TRI-CARB liquid scintillation
analyzer, Packard). For iodide competition experiments, the
incubation buffer was modified as specified in Table 1; where
indicated, inhibitors were dissolved in DMSO and added to
the incubation buffer at the appropriate final concentration.
The total protein content of cells in each well was measured by
Bradford method and used for normalization of the chloride
uptake (expressed as pmol Cl-/µg protein). The uptake
experiments were made, as described above, after 2 minutes of
incubation with 36Cl-. It is important to note, that within this
time frame (data points at 10, 30 and 120 seconds) the 36Cl-
uptake in HEK293-Phoenix and WRO cells is linear (data not
shown), suggesting an unidirectional (inward directed) flux of
chloride, which therefore is not contaminated by a 36Cl- efflux
[14]. To determine non-specific binding, chloride uptake was
measured in SLC26A4 transfected HEK293-Phoenix cells (n=40)
and in control cells (n=40) after 10 seconds and 2 minutes of
incubation; uptake kinetics were interpolated by linear
regression, and the theoretical uptake at time 0 (non-specific
binding) was calculated as intercept on the y-axis. Non-specific
binding was not statistically different between SLC26A4
transfected cells and control cells, and was 127±31 pmol Cl-/µg
protein (n=80). The specific uptake obtained in every experiment
has been corrected for this value (for WRO cells the non-
specific binding was 32±11 pmol Cl-/µg protein; n=10).
Fig. 1. SLC26A4 is expressed in HEK293-Phoenix and WRO
cells. (a) RNA was prepared from HEK293-Phoenix cells and
subjected to reverse-transcription (for the primer pair, see
Material and Methods). The specificity of the reaction was
controlled by sequencing the amplification product. (b) RT-
PCR of SLC26A4 in HEK293-Phoenix and WRO cells. The
amount of SLC26A4 mRNA in both cell systems seems to be
similar if compared to the mRNA of ß-actin. (c) SLC26A4 protein
is expressed in both cell types (the western-blot of rat kidney
SLC26A4 is added as a size control).
Immunocytochemistry and co-localization
For the immunofluorescence assays, cells were washed
30 hours after transfection with 2 ml PBS at room temperature,
fixed for 15 min in 3% paraformaldehyde, permeabilized for 3
min with 0.1% Triton X-100 and blocked 1 hour at room
temperature in PBS/3%BSA. For immunocytochemistry
experiments, coverslips were incubated overnight at 4 °C with
Alexa Fluor 488 coupled anti His-tag mouse monoclonal
antibody (Penta HisTM Alexa Fluor® 488 Conjugate, Qiagen,
Germany) diluted 1:400 in PBS/0.1%BSA. For co-localization
studies EYFP-mem was used. This is a fusion protein consisting
of the N-terminal 20 amino acids of neuromodulin, also called
GAP-43, and a yellow-green fluorescent variant of the enhanced
green fluorescent protein (EGFP). Expression of EYFP-mem in
mammalian cells results in strong labelling of plasma membrane;
however, during the different steps of its trafficking, it also
c
b
a
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Fig. 2. Chloride uptake in HEK293-Phoenix and WRO cells
over-expressing SLC26A4. (a) The chloride uptake is given 2
minutes after incubating the cells with the radioisotope
(2 µCi/ml 36Cl-). Control-experiments were made by using cells
transfected with the empty plasmid expressing solely EGFP.
The expression of SLC26A4 leads to a sevenfold increase of
the chloride uptake in HEK293-Phoenix cells (left panel). The
increase of chloride uptake in WRO cells (right panel) was
smaller if compared with HEK293-Phoenix cells, most likely due
to the lower transfection efficiency obtained in WRO cells if
compared to HEK293-Phoenix cells (see text). For these and all
subsequent chloride flux measurements, the non-specific
binding (see Material and Methods) was subtracted from the
respective values. (b) The transfection efficiency was measured
by the simultaneous expression of SLC26A4 and EGFP by using
an IRES-vector (here shown for HEK293-Phoenix cells; see also
Material and Methods). On the left the transmission image is
given, on the right, the respective green fluorescence (EGFP)
in the positively transfected cells. Scale bar: 50 µm.
(**= p<0.001).
Fig. 3. Expression of exogenous SLC26A4 in HEK293-Phoenix
cells. (a) The His-tagged SLC26A4 was visualized by using
anti-His-tag antibodies. In these experiments SLC26A4 was
not coexpressed with EGFP. On the left panel the transmission
image is given, on the right the respective confocal image of
the fluorescence of the anti-His-tag antibody (labelled with
Alexa 488; green signal); scale bar: 20 µm. (b) The subcellular
localization was done by co-expressing His-tagged SLC26A4
(Alexa 568; red signal) together with EYFP-mem, a EYFP
conjugated membrane label (green signal). Two different cells
are shown, and the arrows indicate membrane bound SLC26A4;
scale bar: 16 µm.
partially labels intracellular membranes. After (50 hours) double
transfection with pTARGET-SLC26A4 and pEYFP-mem
plasmids, cells were treated as described above, and incubated
overnight at 4 °C with anti His6 mouse monoclonal antibody
(Roche) diluted 1:100 in PBS/0.1%BSA. Then, coverslips were
washed three times in PBS and incubated for 2 hours at room
temperature with Alexa Fluor 568 coupled goat anti-mouse
secondary antibody (Invitrogen) diluted 1:100 in PBS/
0.1%BSA.
Conventional and confocal microscopy
Transfection efficiency was determined by visualizing
EGFP transfected cells with an inverted microscope (Axiovert
135, Zeiss) equipped for incident-light fluorescence with a xenon
lamp (XBO 75 W) and 09 series Zeiss filters. Fluorescence
images were obtained with a Leica TCSNT confocal microscope;
focal series of horizontal planes of section were monitored using
an Ar/Kr laser (blocking filter BP 530/30 for Alexa Fluor 488,
EGFP, EYFP; blocking filter LP 590 for Alexa Fluor 568).
a
b
a
b
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Fig. 4. Iodide
competition of chlo-
ride uptake in
H E K 2 9 3 - P h o e n i x
cells. The chloride
uptake was measured
by adding 1 mM and 5
mM sodium-iodide to
the extracellular
solution, respectively
(a and b), and the
respective values were
corrected for the
unspecific binding. In
addition, the chloride
uptake was measured
by substituting 92
mM or 137 mM of
NaCl with respective
amounts of sodium-
iodide, or sodium-
gluconate (c and d;
these values were not corrected by the unspecific binding, which was determined at an extracellular chloride concentration of 135
mM chloride); n.s. = non significant, * = p<0.05, and ** = p<0.01.
Drugs and chemicals
NPPB (5-Nitro-2-(3-phenylpropylamino)benzoic acid),
DIDS (4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid
disodium salt hydrate), niflumic acid, DMSO (Dimethyl
sulfoxide) and all salts were purchased from Sigma (St Louis
MO, USA). 36Cl- (sodium chloride solution) was obtained from
Amersham, UK; OptiPhase ‘HiSafe’ 3 liquid scintillation cocktail
was from Perkin Elmer.
Statistical Analyses
Data are expressed as arithmetic means ± S.E. Statistical
analysis was made by the unpaired or, where applicable, paired
t test. Statistically significant differences were assumed at
p < 0.05.
Results
Endogenous SLC26A4 expression in HEK293-
Phoenix and WRO cells
The SLC26A4 protein is expressed under native
conditions in the kidney [15-20], and here we show, using
RT-PCR, that the SLC26A4 is, in addition, expressed in
human-embryonic-kidney (HEK293-Phoenix) cells. The
amplification product is shown in figure 1a. The specificity
of the approach was proven by sequencing the
amplification product. This procedure confirmed that the
obtained DNA sequence from HEK293-Phoenix cells
corresponds to the sequence of human SLC26A4 (data
not shown). Similarly, the transcription of SLC26A4
mRNA was also proven in WRO cells, a cell-line derived
from the human thyroid (figure 1b). RT-PCR, suggested
similar transcription levels of SLC26A4 in HEK293-
Phoenix and WRO cells (figure 1b). These results were
reconfirmed by Western-blots using anti-pendrin
antibodies (pAb 827 IgG; kindly provided by B. Rousset
[12]) demonstrating that in both cell lines the SLC26A4
protein is indeed expressed (figure 1c).
SLC26A4 overexpression in HEK293-Phoenix
and WRO cells leads to an increased chloride
uptake
As shown in figure 2a, the overexpression of
SLC26A4 leads to a high, and statistically significant,
increase of the chloride uptake. If compared to HEK293-
Phoenix cells expressing only the reporter EGFP protein,
the chloride uptake in cells expressing both, EGFP as well
as SLC26A4 (two separate proteins, see material and
methods) is sevenfold increased, i.e. the chloride uptake
increases from 39 ± 7 pmol chloride /µg protein (n=141)
to 276 ± 14 pmol chloride /µg protein (n=146). The
transfection efficiency in our experiments was 54.7 ±
3.7% (n=27) measured by fluorescence means,
determining the number of cells showing the signal induced
by EGFP (figure 2b), therefore the sevenfold increase of
chloride uptake underestimates the real effect induced
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by the expression of the SLC26A4 protein. In WRO cells,
overexpression of SLC26A4 leads to an increase of
chloride uptake from 125.7 ± 14.9 pmol chloride /µg protein
in control cells (n=24), to 218.9 ± 16.7 pmol chloride /µg
protein in SLC26A4 expressing cells (n=24), respectively.
For the latter, the transfection efficiency was 5-10%,
which is significantly lower if compared to HEK293-
Phoenix cells, and could therefore explain the weaker
increase of chloride uptake observed in WRO cells.
Expression and subcellular localization of
exogenous SLC26A4 in HEK293-Phoenix cells
Western-blot experiments using HEK293-Phoenix
cells demonstrated that the transfection of SLC26A4 as
well as of the SLC26A4S28R mutant leads to an
overexpression of the respective protein (see below).
Furthermore, the expression of exogenous SLC26A4 in
HEK293-Phoenix cells was verified by
immunocytochemistry and visualized by using a His-
tagged form of the protein (figure 3a). The His-tag was
added to the C-terminus, which is located in the cytosol
[4, 5]. At the sub-cellular level, SLC26A4 immuno-
reactivity is highest in cytoplasmic vesicles (figure 3b).
However, as shown in figure 3b, a fraction of the
expressed protein is located at the level of the
cytoplasmatic membrane, the functional compartment of
the anion exchanger. This finding is substantiated by
Western-blots using plasma membrane preparations of
HEK293-Phoenix cells (see figure 6c).
Iodide competes with chloride for the uptake
It has been shown, that besides chloride, the
SLC26A4 protein is also able to transport I-, HCO3
-, OH-
and formate- [20-22]. The HCO3
-, formate, OH-, as well
as chloride transports were also verified by expressing
the SLC26A4 protein in HEK293-Phoenix cells [20]. Here
we characterize for the first time the influence of iodide
on the chloride uptake in HEK293-Phoenix cells. As
shown in figures 4a and b, neither the addition of 1 mM
nor 5 mM iodide to the extracellular fluid is able to
significantly change the chloride uptake. In order to test
higher concentrations of iodide, i.e. 92 mM or 137 mM,
we substituted extracellular unlabeled chloride with
gluconate or with iodide. This procedure was chosen to
prevent osmotic perturbations after adding iodide and to
unmask the iodide effect. As shown in figures 4c and d,
the presence of 92 mM or 137 mM iodide leads to a
marked and significant reduction of chloride uptake (from
174 ± 12 pmol chloride /µg protein (n=10) to 97 ± 5 pmol
chloride /µg protein (n=10), and from 328 ± 28 pmol
Fig. 5. Chloride uptake in HEK293-Phoenix cells measured in
the presence of known chloride-transport blockers. NPPB (0.1
mM; a), as well as niflumic acid (0.1 mM; b), are able to reduce
SLC26A4 induced chloride uptake. DIDS (0.5 mM; c) is not
able to reduce SLC26A4 induced chloride uptake, however, the
chloride uptake in control cells can be blocked by the drug;
n.s. = non significant, * = p<0.05, and ** = p<0.01.
chloride/µg protein (n=8) to 54 ± 10 pmol chloride/µg
protein (n=8), for 92 mM and 137 mM iodide respectively)
to an amount, which is indistinguishable from the uptake
in the presence of the respective amount of iodide in
control cells (92 ± 13 pmol chloride/µg protein (n=10),
and 43 ± 6 pmol chloride/µg protein (n=8), for 92 mM
and 137 mM iodide, respectively). These results are in
accordance with the hypothesis that iodide, like chloride,
can be transported by SLC26A4.
In the control cells, which are not transfected with
SLC26A4, iodide, as described above, is again able to
reduce significantly the chloride uptake (figure 4c and
d). A possible explanation for this finding is that iodide
also competes with the endogenous Cl- transport systems,
that contribute to the overall Cl- uptake in these cells
(figure 5c).
Functional Characterization of Wild-Type and Mutated Pendrin
a
b
c
Cell Physiol Biochem 2006;17:245-256
D
ow
nl
oa
de
d 
by
: 
15
9.
14
9.
19
2.
11
6 
- 5
/3
/2
01
6 
2:
31
:2
6 
PM
252
Fig. 6. Functional characterization of the SLC26A4S28R mutant of SLC26A4 in HEK293-Phoenix as well as WRO cells. (a) The
chloride uptake of SLC26A4S28R, compared to wild-type, is markedly reduced, if expressed in both, HEK293-Phoenix or WRO cells.
(b) The expression pattern of SLC26A4S28R is similar to wild-type SLC26A4 (see figure 3). On the upper left side, the transmission
image is given, the corresponding fluorescence image, obtained from the anti-His-tag antibody is shown on the right side (the
green signal indicates the SLC26A4 expression); scale bar: 20 µm. Below, the co-localization of SLC26A4S28R (red signal), and
EYFP-mem (green signal) are given; scale bar: 16 µm (for details, see figure 3). (c) Both, wild-type SLC26A4 as well as the tested
mutant are expressed at the level of the plasma membrane. Western-blots of wild-type (SLC26A4; three different preparations)
and mutant SLC26A4 (SLC26A4S28R; four different preparations) in isolated plasma membranes are shown. (n.s. = non significant,
* = p<0.05, and ** = p<0.01).
SLC26A4 dependent chloride uptake can be
blocked by NPPB, and niflumic acid but not by
DIDS
NPPB as well as niflumic acid are known blockers
of chloride transport in a variety of different cells [23-
25]. The chloride uptake in cells over-expressing the
pendrin protein was tested in the presence of both
substances (figure 5a and b). Both blockers applied at
concentration of 0.1 mM, are able to reduce the chloride
uptake, i.e. by 59.3±8.4%, n=36 (NPPB; 0.2% DMSO;
DMSO alone has no effect on the chloride uptake, data
not shown) and 69.9±4.5%, n=20 (niflumic acid; 0.1%
DMSO). In contrast, 0.5 mM DIDS (0.5% DMSO) is
not able to significantly impair the SLC26A4 induced
chloride uptake (n = 46), whereas the chloride uptake in
control-cells not over-expressing SLC26A4 is completely
blocked (n = 45).
Functional characterization of a mutated (S28R)
SLC26A4 protein
As shown in figure 6a, the chloride uptake measured
in HEK293-Phoenix cells expressing the mutated form
of SLC26A4 (SLC26A4S28R) is markedly reduced
(by ~80%), if compared to HEK293-Phoenix cells
expressing the wild-type form of SLC26A4 (from 281±
14 pmol chloride /µg protein (n=20) to 48 ± 16 pmol
chloride /µg protein (n=18), respectively). The transfection
efficiency of SLC26A4S28R transfected HEK293-Phoenix
cells (54.6 ± 4.5, n=28) is statistically not different to wild-
type SLC26A4 transfected HEK293-Phoenix cells.
Similarly the chloride uptake was also measured in WRO
cells expressing wild-type or mutant SLC26A4. As in the
case of HEK293-Phoenix cells, the chloride uptake
measured in WRO cells expressing SLC26A4S28R is
markedly lower if compared to WRO cells expressing
wild-type SLC26A4 (107 ± 24.5 pmol chloride /µg protein;
n=10, and 218.9 ± 16.7 pmol chloride/µg protein; n=24,
respectively) and not significantly different from control
WRO cells (125.7 ± 14.9 pmol chloride /µg protein; n=24).
The expression pattern of SLC26A4S28R is
indistinguishable from the pattern of wild-type SLC26A4
(figure 6b). Western-blot experiments confirmed that
significant amounts of SLC26A4S28R protein could be
detected at the plasma membrane level (figure 6c).
a b
c
Dossena/Vezzoli/Cerutti/Bazzini/Tosco/Sironi/Rodighiero/Meyer/
Fascio/Fürst/Ritter/Fugazzola/Persani/Zorowka/Storelli/Beck-Peccoz/
Bottà/Paulmichl
Cell Physiol Biochem 2006;17:245-256
D
ow
nl
oa
de
d 
by
: 
15
9.
14
9.
19
2.
11
6 
- 5
/3
/2
01
6 
2:
31
:2
6 
PM
253
Discussion
Despite the obvious clinical relevance of SLC26A4,
the detailed function of the SLC26A4 transporter is still
elusive, particularly in respect to its function in different
organs in which it is expressed. In the inner ear SLC26A4
is expressed in the cochlear external sulcus cells,
vestibular transition cells and endolymphatic sac cells [26,
27]. These cells are involved in the conditioning of the
endolymphatic fluid and in these cells the SLC26A4
transporter is most likely acting as a Cl-/HCO3- exchanger.
In the kidney, SLC26A4 is located in the apical membrane
of β-intercalated cells [17-19]. There, SLC26A4 seems
to be involved, amongst other important transporters like
AE1 and AE4 [28-30] in bicarbonate transport, which is
activated in metabolic alkalosis and inactivated in
metabolic acidosis [19, 31], most likely by a process called
‘plasticity of epithelial polarity’ [32, 33]. In the thyroid
gland, SLC26A4 is expressed in the thyrocytes, where it
has been shown that SLC26A4 resides in the apical
membrane [4]. This membrane is facing the follicular
lumen into which the exchanger is supposed to transport
iodide that will then be organified on thyroglobulin.
Thyroglobulin, after reabsorption into the thyrocytes, will
be modified by lysosomal degradation and transformed
to thyroid hormones [34, 35].
The aim of the present study was to compare, on a
functional level, wild-type SLC26A4 with a mutant form
(SLC26A4S28R). Several different studies were made using
the expression of the SLC26A4 protein in non-polarized
human-embryonic-kidney (HEK) cells [20, 36, 37],
claiming, that the SLC26A4 protein is not expressed in
those cells [4, 20]. Here we show, that the SLC26A4
protein is expressed in non polarized HEK293-Phoenix
as well as in non-polarized WRO cells [13], and therefore
we can assume that these cells also possess the
environment needed for SLC26A4 function (despite the
fact that the cells we use are not polarized). This is
particularly important for the present study, since we
would like to investigate a mutated form of SLC26A4,
i.e. SLC26A4S28R, which bears the mutation in the N-
terminal, i.e. the cytoplasmatic part of the protein [4].
The use of cell lines that are able to functionally express
the SLC26A4 protein are therefore advantageous for the
functional comparison of wild-type and mutated
transporter.
In both non-polarized cell lines, i.e. HEK293-Phoenix
and WRO, the expression of SLC26A4 leads to an
increased chloride uptake, which is in agreement with
the hypothesis, that the protein acts as a chloride-
transporter [19, 20]. From the experiments reported here,
however, we can not speculate whether the transporter
is electroneutral or electrogenic as proposed by Ko [38]
and Yoshida [39]. However, we recently showed, that
SLC26A4 expressed in HEK293-Phoenix cells is
electroneutral [40].
At the sub-cellular level, SLC26A4 immuno-
reactivity is highest in cytoplasmic vesicles of the cell
line tested. This finding is well in agreement with previous
observations in kidney cells [16, 18, 41-43] and
endometrium [44], using antibodies against pendrin. The
localization of wild-type or mutated SLC26A4-GFP was
also reported in non-polarized HeLa cells [36], as well as
COS7 and FRTL5 cells . In the latter study, different
cytosolic expression patterns of wild-type SLC26A4 were
observed, depending on the cell line used. Whereas in
COS7 cells the subcellular expression was located
predominantly at the endoplasmatic reticulum, the
subcellular expression in FRTL5 cells is located at the
Golgi complex [45]. The subcellular expression pattern
seems therefore to depend on the cell type used, and is
most likely the result of the slow-folding process involved
in SLC26A4 overexpression, leading therefore to
aggregate formation [46]. However, in all studies reported
so far, including the present, SLC26A4 can also be
individuated at the level of the cell membrane which
corresponds to the functional compartment of the anion-
exchanger.
It has been shown, that besides chloride, the
SLC26A4 protein is also able to transport I-, HCO3
-, OH-
and formate- [20-22]. The vectorial transport of iodide
by pendrin has been demonstrated in polarized cells [5].
Conflicting reports are reported about a possible
competition between iodide and chloride on the transport
level of SLC26A4. Whereas Yoshida and collaborators
do not observe such a competition [47], the expression of
human SLC26A4 in both Xenopus oocytes and Sf9 cells
seems to mediate chloride as well as iodide transport [21].
In accordance to the latter study, our results obtained in
experiments in which chloride was substituted by iodide
are in accordance with the hypothesis that iodide can
indeed be transported by SLC26A4.
So far only some of the known blockers of anion
transporters have been tested on SLC26A4, i.e. DIDS,
furosemide and probenecid, which lead to a relatively
weak ion-transport inhibition [21, 48]. Therefore we
investigated the effects of additional inhibitors, which have
so far not been tested on SLC26A4 before, and could
thus help to develop a pharmacological ‘fingerprint’ of
the SLC26A4 function. This is the first time that niflumic
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acid or NPPB were tested in SLC26A4 expressing cells,
and we show, that both blockers applied at concentration
of 0.1 mM, are able to reduce the chloride uptake. It was
reported, that micro-molar concentrations of niflumic acid
are able to reduce the SLC26A3 (DRA) induced ion
transport. DRA is the most similar SLC26 protein to
pendrin (45% amino acid identity), and whose inhibition
by DIDS is controversial [49]. It is important to note, that
in our experiments, 0.5 mM DIDS is not able to impair
the SLC26A4 induced chloride uptake, whereas the
chloride uptake in control cells not over-expressing
SLC26A4 is completely blocked. This underlines the
assumption, that in control cells, under the conditions used,
the chloride uptake in the absence of pendrin over-
expression is mainly supported by transporters other than
SLC26A4, which are DIDS sensitive. So far the DIDS
sensitive chloride uptake in cells over-expressing
SLC26A4 was only tested in oocytes [21]. In contrast to
our finding, in the latter, the pendrin induced chloride
uptake was sensitive to DIDS. The different cellular
system in which the SLC26A4 was over-expressed, and
in addition the fact that the DIDS effect was studied in
the virtual absence of extracellular chloride, or the higher
DIDS concentration (1 mM) used in the oocyte study,
might explain the observed discrepancy. Defining the
functional pattern of SLC26A4 modulators can help to
provide a pharmacological tool for characterizing the
involved transport pathways.
Recently we have described a mutation in the
SLC26A4 protein associated with goiter and positive
perchlorate test, hypothyroidism, and severe sensorineural
hearing loss, associated with enlargement of the vestibular
aqueduct and of the endolymphatic duct and sac [9]. The
patient showed a biallelic missense mutation in exon 2
leading to the substitution of a serine for an arginine
(SLC26A4S28R). The parents of the patient showed the
same mutation in heterozygous form [9]. No chloride
uptake studies of SLC26A4 mutants are described so far
in human expression systems. The three mutants
described by Rotman-Pikielny and collaborators were all
retained in the subcellular compartment [45] and in this
study no functional assays were used. Taylor and
collaborators investigated the iodide efflux in cells co-
expressing SLC26A4 mutants together with NIS, a known
sodium/iodide cotransporter [50, 51]. Most of the mutants
used in this study displayed complete loss of pendrin
induced iodide transport [36]. Scott and collaborators
tested the chloride and iodide uptake of SLC26A4 mutants
expressed in Xenopus laevis oocytes [52], and compared
the respective uptakes with oocytes expressing wild-type
pendrin. For three mutants associated with Pendred
syndrome (T416P, L236P and E384G) no different chloride
or iodide uptake could be observed compared to control
cells, however, for mutants observed in patients with non-
syndromic hearing loss (DFNB4; I490L, G497S, V653A
and V480D), the chloride as well as iodide uptake was
reduced. These studies clearly demonstrate the need for
functional studies of the transport features of SLC26A4
mutants in mammalian expression systems. Here we
show, that SLC26A4 and the S28R mutant we used are
transposed towards the membrane, and that the mutation
leads to a marked reduction of the transport capabilities
of the ion exchanger. The mechanism by which the S28R
mutation is leading to the observed reduced chloride
transport is not clear yet. Further studies are needed for
getting detailed insight into the involved mechanisms.
Conclusions
The SLC26A4 protein is a chloride/anion exchanger
involved in iodide translocation from the cell to the colloid
in the thyroid gland, and responsible for the conditioning
of the endolymphatic fluid in the inner ear. Malfunction
of the protein leads to Pendred syndrome, a disease
complex characterized by deafness and impaired iodide
organification. Here we show, that the SLC26A4 induced
chloride uptake in HEK293-Phoenix cells competes with
iodide, and can be blocked by NPPB and niflumic acid,
whereas DIDS is unable to reduce the SLC26A4 induced
chloride uptake. Furthermore, we show for the first time
a direct functional characterization of a SLC26A4 mutant
(SLC26A4S28R) we described recently. This mutant is
transposed towards the cell membrane, but its transport
capability (chloride uptake) is markedly reduced compared
to wild-type SLC26A4. The functional characteristics of
SLC26A4S28R we described, are consistent with the clinical
phenotype observed in the patient.
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